NRX, $0.54, moving, O/S: 13 m. IPO at $12 and went high to $18.
It completed an initial public offering, selling shares for $12 and raising $33 million. By the fourth quarter that year, shares traded as high as $17.98. Using Dec. 31, 2014, as a date of demarcation, NephroGenex was the best-performing IPO of the five Triangle companies to go public that year, a group that included high fliers like INC Research and PRA Health Sciences.
Huge bouncing back to dollars!!!